SCHEMBL30037998

SCHEMBL30037998

O=C(N[C@@H](Cc1ccccc1)C(=O)O)c1cccnc1

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR132 Q9UNW8 9/20 0.69
ECE1 P42892 1/20 0.68
CMKLR2 P46091 1/20 0.68
CMKLR1 Q99788 1/20 0.68
LMNA P02545 1/20 0.61
CTRC Q99895 1/20 0.60
ACE P12821 2/20 0.59
PTPN1 P18031 1/20 0.58
AGTR2 P50052 2/20 0.58
CYP3A4 P08684 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
MEN1 O00255 1/20 0.57
NPC1 O15118 1/20 0.57
RAB9A P51151 1/20 0.57
KMT2A Q03164 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3497405 1.00 GPR132 (0.69) GPR132ECE1CMKLR2CMKLR1LMNA
SCHEMBL2229201 1.00 GPR132 (0.69) GPR132ECE1CMKLR2CMKLR1LMNA
SCHEMBL10659411 0.92 GPR132 (0.72) GPR132ECE1CMKLR2CMKLR1ACE
SCHEMBL30037402 0.91 GPR132 (0.61) GPR132ECE1CMKLR2CMKLR1LMNA
SCHEMBL6860313 0.91 GPR132 (0.61) GPR132ECE1CMKLR2CMKLR1LMNA
SCHEMBL23489730 0.89 ECE1 (0.65) GPR132ECE1CMKLR2CMKLR1LMNA
SCHEMBL7415738 0.88 ECE1 (0.64) GPR132ECE1CMKLR2CMKLR1LMNA
SCHEMBL27520437 0.88 ECE1 (0.64) GPR132ECE1CMKLR2CMKLR1LMNA
Leucine SCHEMBL1406326 0.88 GPR132 (0.56) GPR132ECE1CMKLR2CMKLR1LMNA
SCHEMBL6860349 0.87 ECE1 (0.62) GPR132ECE1CMKLR2CMKLR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230355550-A1 KETAMINE COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM ALTER DOMUS (US) LLC 2023-11-09 US disclosed
US-11753378-B2 Ketamine compounds and processes for making and using them ZEVRA THERAPEUTICS, INC. (US) 2023-09-12 US disclosed
US-20220348544-A1 KETAMINE COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM ALTER DOMUS (US) LLC 2022-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11753378-B2 Ketamine compounds and processes for making and using them OPRK1, GRIK3, GRIN3B GPR132 2192/4885ECE1 1292/4885CMKLR2 2627/4885
US-20230355550-A1 KETAMINE COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM OPRK1, GRIK3, GRIN3B GPR132 2192/4885ECE1 1292/4885CMKLR2 2627/4885
US-20220348544-A1 KETAMINE COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM OPRK1, GRIK3, GRIN3B GPR132 2192/4885ECE1 1292/4885CMKLR2 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.